COCP News and Press, Cocrystal Pharma Inc. From 04/21/22

Cocrystal Pharma (NASDAQ:COCP) signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies evaluating the potential of  its 3CL protease inhibitors to treat COVID-19. The company said it applied its proprietary drug discovery platfor...

BOTHELL, Wash., April 21, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory...

BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at the hybrid in-person and virtual Life Science Innovation Northwest 2022 (LSINW) ...

BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the NobleCon18—Noble Capital Markets’ Eighteenth Ann...

First Data From Influenza Program Reported. Cocrystal reported preliminary data from the Phase 1 clinical trial testing CC-42344, its oral antiviral for pandemic and seasonal influenza A. This is an orally administered drug that targets viral polymerase, blocking an early step in the viral lif...

Cocrystal Pharma (NASDAQ:COCP) said preliminary data from a phase 1 study of CC-42344 showed a favorable safety and pharmacokinetic profile of the oral antiviral for pandemic and seasonal influenza A. The company said the ongoing phase 1 trial plans to enroll 56 healthy adults. Results from t...

CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile BOTHELL, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Compa...

Cocrystal Pharma provides a preview of their upcoming presentation at NobleCon18 NobleCon18 - Noble Capital Markets 18th Annual Small and Microcap Investor Conference - April 19-21, 2022 - Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | ...

Cocrystal Pharma press release (NASDAQ:COCP): FY GAAP EPS of -$0.16 in-line. The Company reported unrestricted cash of $58.7 million as of December 31, 2021, compared with $33.0 million as of December 31, 2020. For further details see: Cocrystal Pharma GAAP EPS of -$0.16 in-line

Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza A Advanced COVID-19 programs with the goal of initiating two Phase 1 trials in 2022 with the intranasal/pulmonary antiviral ...